Business
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
MOUNTAIN VIEW, Calif., March 26, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (JV
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/aca51dad1258f951a88885de68c1340c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MR_s1kK23719slWPROFzPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/aca51dad1258f951a88885de68c1340c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9GKuGF7dlD3QBh9EjqFi3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/aca51dad1258f951a88885de68c1340c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Peer-reviewed paper will be honored as a Journal of Vascular and Interventional Radiology Award-Winning Paper","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"Pre-clinical data show that TAMP increases intra-arterial pressure, improving drug delivery with 100-fold increase in local tissue concentration of the therapy","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of existing and new treatments","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 26, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (JVIR) Award-Winning Paper Scientific Session during the upcoming Society of Interventional Radiology (SIR) 2025 Annual Scientific Meeting.","length":673,"tagName":"p"},{"type":"text","content":"The peer-reviewed paper, published in the July 2024 edition of JVIR, is being honored during the conference’s JVIR Award-Winning Paper Scientific Session in Nashville, TN, scheduled at 3:00-4:30 PM CT on Tuesday, April 1, 2025. The session will be moderated by Daniel Sze, MD, PhD, Stanford Universit...